NJA-730
/ NapaJen Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 08, 2020
NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
(GlobeNewswire)
- "The half-life of NJA-730 in blood was approximately 30 minutes, with the drug being rapidly eliminated from circulation. Based on these positive findings, NapaJen intends to initiate a Phase 2 clinical trial of NJA-730 for the prevention of acute graft-versus-host disease (aGvHD) in 2021."
New P2 trial • Graft versus Host Disease • Immunology
1 to 1
Of
1
Go to page
1